JEIL PHARMACEUTICAL CO.,LTD Q3 operating loss of KRW 6.3 billion, turning to a loss; sales of KRW 136.7 billion
AI summary · Not investment advice
Jeil Pharmaceutical sold KRW 136.7 billion in Q3 but lost KRW 6.3 billion from its main business, down from a profit a year earlier.
Operating profit · 3 months
KRW -6.3 billion
Key facts
- Revenue (3 months)
- KRW 136.7 billion
- Net income (3 months)
- KRW -9.8 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 134.8 billion
- Revenue (year to date)
- KRW 413.6 billion
- Operating profit (prior-year 3 months)
- KRW 9.8 billion
- Operating profit (year to date)
- KRW -12.9 billion
- Net income (prior-year 3 months)
- KRW 15.9 billion
- Net income (year to date)
- KRW -13.2 billion
Commentary
AI commentary · Not investment advice
What happened
Jeil Pharmaceutical reported its consolidated results for the third quarter of 2026. Sales for the latest 3 months were KRW 136.88 billion. Operating profit (profit from the core business) was a loss of KRW 6.25 billion. Net income (final profit after taxes and other costs) was a loss of KRW 9.77 billion.
In the company's terms
Sales for the latest 3 months were up 1.4% from a year earlier. They were down 6.8% from the previous quarter. Sales for the same 3 months a year earlier were KRW 134.76 billion.
What changes for shareholders
Operating profit a year earlier was a profit of KRW 9.82 billion, so it has turned to a loss. Net income a year earlier was a profit of KRW 15.87 billion, and it has also turned to a loss.
For the year to date (January 1 to September 30), sales were KRW 413.59 billion. Operating profit was a loss of KRW 12.88 billion. Net income was a loss of KRW 13.22 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
J